Evidence map›Paper›PMID 41929485›Full record

ArticleFrontiers in immunology2026

Evaluation of the trypanocidal and immunomodulatory effects of LDT409, a cardanol derivative from cashew nut shell liquid.

Juliana Magalhães Chaves Barbosa, Yasmin Pedra-Rezende, Tatiana Galvão Melo, Gabriel Melo de Oliveira, Andressa Souza de Oliveira, Natália Cipriano Monteiro, Luiz Antonio Soares Romeiro, Anissa Daliry, Kelly Salomão

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Juliana Magalhães Chaves BarbosaLaboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
Yasmin Pedra-RezendeLaboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
Tatiana Galvão MeloLaboratório de Ultraestrutura Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
Gabriel Melo de OliveiraLaboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
Andressa Souza de OliveiraLaboratório de Desenvolvimento de Inovações Terapêuticas, Núcleo de Medicina Tropical, Universidade de Brasília, Brasília, DF, Brazil.
Natália Cipriano MonteiroLaboratório de Desenvolvimento de Inovações Terapêuticas, Núcleo de Medicina Tropical, Universidade de Brasília, Brasília, DF, Brazil.
Luiz Antonio Soares RomeiroLaboratório de Desenvolvimento de Inovações Terapêuticas, Núcleo de Medicina Tropical, Universidade de Brasília, Brasília, DF, Brazil.
Anissa DaliryLaboratório de Fisiopatologia Clínica e Experimental, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
Kelly SalomãoLaboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chagas disease (CD), caused by Methods: In this study, we evaluated the trypanocidal activity and immunomodulatory effects of LDT409 using Results: Our findings indicate that LDT409 treatment was associated with a reduction in peak parasitemia and with modulation of the host immune response, characterized by a shift toward a Th2/Th17 profile and attenuation of a Th1-driven pro-inflammatory response, concomitant with reduced cardiac damage. Notably, the underlying mechanisms of these effects, including the involvement of PPARs, remain to be clarified. Conclusion: Together, these observations suggest that LDT409 may represent a promising, cost-effective, and sustainable compound for further investigation in the context of Chagas disease.

Indexed as

AnacardiumChagas DiseaseImmunologic FactorsPhenolsTrypanocidal AgentsTrypanosoma cruziAnimalsDisease Models, AnimalFemaleHumansMicecardanolImmunologic FactorsPhenolsTrypanocidal Agentscardanol derivativecashew nut shell liquidChagas diseasechemotherapeutic agent for Chagas diseasenatural productsTrypanosoma cruzi

Identifiers

PMID41929485
PMCPMC13038549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.